Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

NCT ID: NCT02143050

Last Updated: 2023-11-18

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2017-11-17

Brief Summary

The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.

Detailed Description

The study will be a single-arm, single center, uncontrolled phase I/II trial to estimate the safety of the combined treatments and then estimate the efficacy in terms of objective response rate in patients with stage IIIC and Stage IV melanoma treated with dabrafenib/trametinib and metformin.

Conditions

Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dabrafenib, Trametinib and Metformin

Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Dabrafenib

Intervention Type: DRUG

Trametinib

Intervention Type: DRUG

Metformin

Intervention Type: DRUG

Interventions

Dabrafenib

Intervention Type: DRUG

Trametinib

Intervention Type: DRUG

Metformin

Intervention Type: DRUG

Other Intervention Names

Tafinlar; Mekinist; Glucophage

Eligibility Criteria

Inclusion Criteria

• Male or female patients > 18 years of age
• Patients with histologically confirmed BRAFV600E melanoma (Stage IIIC or
• Stage IV, American Joint Commission on Cancer)
• Eastern Cooperative Oncology Group Performance Status of 0 to 2
• Life expectancy > 3 months
• At least 1 site of radiographically measurable disease by RECIST 1.1
• Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing:
• Absolute neutrophil count > 1.0 x 10⁹/L
• Platelet count > 50 x 10⁹/L
• Hemoglobin > 8 g/dL
• Serum creatinine < 2 x upper limit of normal
• Total serum bilirubin < 3 x ULN
• Serum aspartate transaminase or serum alanine transaminase < 3 x ULN, and < 4 x ULN if liver metastases are present
• Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician
• Pre-menopausal females and females < 2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of the study drug
• Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for > 1 year
• Before study entry, written informed consent must be obtained from the patient prior to performing any study related procedures

Exclusion Criteria

• Prior treatment with Vemurafenib or Dabrafenib
• Known hypersensitivity to Metformin or any of its components
• Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment or have not recovered from side effects of all radiation related toxicities to Grade < 1, except for alopecia
• Pregnant, breast feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures
• Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

James Graham Brown Cancer Center

OTHER

Sponsor Role: collaborator

University of Louisville

OTHER

Sponsor Role: lead

Responsible Party

Jason Chesney

Director, James Graham Brown Cancer Center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jason A Chesney, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

James Graham Brown Cancer Center

Locations

James Graham Brown Cancer Center-Universityof Louisville

Louisville, Kentucky, United States

James Graham Brown Cancer Center

Louisville, Kentucky, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

BCC-MEL-14-01

Identifier Type: -

Identifier Source: org_study_id